

We are advancing a diversified portfolio of product candidates derived from our four drug classes focused on the potential treatment of cancer, infectious diseases and other serious diseases of unmet patient need:

Oncology

Orug class	Platform	Product candidate	Indication (target)	Phase 1	Phase 1/2	Phase 2	Phase 3	BioNTech rights ¹	Collaborator/ Partner
mRNA	FixVac	BNT111	Advanced, R/R melanoma						
		BNT113	Metastatic/ R/R HPV16+ head and neck cancer				i	Fully owned ²	
		BNT116	1L metastatic NSCLC Advanced/metastatic NSCLC					i	
	iNeST	BNT122 (autogene cevumeran)	1L advanced melanoma Adjuvant colorectal cancer Adjuvant pancreatic ductal adenocarcinoma Multiple solid tumors					Collaboration	Genentech ³
	RiboMabs	BNT142	Multiple solid tumors (CD3×CLDN6)			i ———	i ———	Fully owned	
	RiboCytokines	BNT151	Multiple solid tumors (IL-2 variant)					-	
		BNT152 + BNT153	Multiple solid tumors (IL-7, IL-2)					Fully owned	
	CAR T cells + CARVac	BNT211	Multiple solid tumors (CLDN6)					Fully owned	
Cell therapies	Neoantigen-based T cells	BNT221	Refractory metastatic melanoma					Fully owned	
Protein- based therapeutics	Next-generation immune checkpoint modulators	BNT311 / GEN1046 (acasunlimab) BNT312 / GEN1042 BNT313 / GEN1053 BNT314 / GEN1059 BNT322 / GEN1056	aPD(L)1-R/R metastatic NSCLC (PD-L1x4-1BB) Multiple solid tumors (PD-L1x4-1BB) Multiple solid tumors (CD40x4-1BB) ⁴ Multiple solid tumors (CD27) Multiple solid tumors (EpCAMx4-1BB) Multiple solid tumors					Collaboration	Genmab
		BNT316 / ONC-392 (gotistobart)	aPD(L)1-R/R metastatic NSCLC (CTLA-4) Platinum-resistant ovarian cancer (CTLA-4) Metastatic castration-resistant prostate cancer (CTLA-4) Multiple solid tumors (CTLA-4)					Collaboration	OncoC4
	Targeted cancer antibodies	BNT321	Adjuvant pancreatic ductal adenocarcinoma (sLea) Metastatic pancreatic cancer (sLea)	oma				Fully owned	
	Antibody-drug conjugates	BNT323 / DB-1303	HR+/HER2-low metastatic breast cancer (HER2) Multiple solid tumors (HER2) Multiple solid tumors (B7H3)					Collaboration	Duality Biologics
		BNT324 / DB-1311							
		BNT325 / DB-1305	Multiple solid tumors (TROP2)					!	
		BNT326 / YL202	Multiple solid tumors (HER3)			i ————————————————————————————————————		Collaboration	MediLink Therapeutics
SMI ⁵	Toll-like receptor binding	BNT411	Multiple solid tumors (TLR7)					Fully owned	Thorapoullos



We are advancing a diversified portfolio of product candidates derived from our four drug classes focused on the potential treatment of cancer, infectious diseases and other serious diseases of unmet patient need:

Infectious Diseases

Drug class	Product candidate	Indication	Phase 1	Phase 1/2	Phase 2	Phase 3	Commercial	BioNTech rights	Collaborator/ Partner
mRNA	BNT162b2							I	
	BNT162b2+BNT162b4			į	į	į	į	!	Pfizer
	(T-cell enhancing)	COVID-19		i	i	i	i	Collaboration	Fosun Pharma
	BNT162b5/6/7			!	<u>!</u>	I I	I I		
	(Stabilized spike antigen)			<u> </u>			<u> </u>	l	
	BNT162b2+BNT161 ⁶	COVID-19 - Influenza		<u>i </u>	i	<u>i </u>	i	Collaboration	Pfizer
		combination					l		
	BNT161	Influenza				<u> </u>	I	Collaboration ⁷	Pfizer
	BNT163	HSV		į	į	į	į	Collaboration	University of
				i	i	! !	! !		Pennsylvania
	BNT164	Tuberculosis ⁸		1	I I	I I	I I	Fully owned	Funded by Bill &
				İ	į	į	į		Melinda Gates
				i	i	i	i	! !	Foundation
	BNT165	Malaria ⁹			<u> </u>	I	I	Fully owned	
	BNT166	Mpox						Fully owned	Funded by CEPI ¹⁰
	BNT167	Shingles			i	i	i	Collaboration	Pfizer

¹ For further details about BioNTech's rights see quarterly reports under https://investors.biontech.de/financials-filings/quarterly-reports.

² FixVac platform is fully owned by BioNTech. The BNT111 and BNT116 Phase 2 trials are jointly conducted with Regeneron as part of a cost-sharing strategic collaboration.

³ A member of the Roche group

⁴ Two Phase 1/2 clinical trials in patients with solid tumors are ongoing in combination with ICI+/- chemotherapy.

⁵ Small molecule immunomodulators

⁶ The COVID-19-Influenza combination is a Phase 3 trial in partnership with Pfizer. Further development is subject to entering into a definitive agreement.

⁷ Out-licensed to Pfizer

⁸ Two Phase 1 clinical trials are ongoing (NCT05537038, Germany and NCT05547464, Republic of South Africa).

⁹ A Phase 1 clinical trial (NCT05581641) and a Phase 1/2 clinical trial (NCT06069544) are ongoing.

¹⁰ Coalition for Epidemic Preparedness Innovations (CEPI)